Transave Inc., a biopharmaceutical company developing inhaled liposomal formulated drugs for treating life threatening lung disease, today announced the appointment of Donald J. Hayden, Jr. as executive chairman of the company’s Board of Directors. Hayden is a veteran of the pharmaceutical industry bringing valuable experience and perspective gained during his successful 25-year tenure at Bristol Myers Squibb, including 15 years in senior executive positions.
